ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-646-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$593.75 million
Profitability
Miscellaneous
Employees1,143
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) released its earnings results on Thursday, January, 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03. The medical equipment provider had revenue of $200.56 million for the quarter, compared to the consensus estimate of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
How can I listen to ABIOMED's earnings call?
ABIOMED will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8552122361.
What guidance has ABIOMED issued on next quarter's earnings?
ABIOMED issued an update on its FY 2019 earnings guidance on Thursday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $780-780 million, compared to the consensus revenue estimate of $774.79 million.
What price target have analysts set for ABMD?
4 analysts have issued 1-year price targets for ABIOMED's shares. Their predictions range from $400.00 to $480.00. On average, they anticipate ABIOMED's stock price to reach $450.25 in the next year. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Price Targets for ABIOMED.
What is the consensus analysts' recommendation for ABIOMED?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.
Has ABIOMED been receiving favorable news coverage?
Media headlines about ABMD stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting ABIOMED?
ABIOMED saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,982,316 shares, an increase of 36.5% from the March 29th total of 1,452,245 shares. Based on an average trading volume of 701,074 shares, the days-to-cover ratio is currently 2.8 days. Approximately 4.5% of the company's stock are short sold. View ABIOMED's Current Options Chain.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Haemonetics (HAE), Novocure (NVCR), Tandem Diabetes Care (TNDM) and Merit Medical Systems (MMSI).
What other stocks do shareholders of ABIOMED own?
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
- Dr. David M. Weber, Chief Operating Officer (Age 58)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
- Mr. William J. Bolt, Exec. Officer (Age 67)
- Mr. Ian McLeod, VP & Corp. Controller
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.26%), Columbus Circle Investors (0.25%), Country Trust Bank (0.24%), Strs Ohio (0.23%), Rhenman & Partners Asset Management AB (0.21%) and Retirement Systems of Alabama (0.20%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which major investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Strs Ohio, Meeder Asset Management Inc., Nisa Investment Advisors LLC, Roman Butler Fullerton & Co., Dorsey Wright & Associates, QUANTRES ASSET MANAGEMENT Ltd and Advisor Partners LLC. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.
Which major investors are buying ABIOMED stock?
ABMD stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Rhenman & Partners Asset Management AB, Scout Investments Inc., Mercer Global Advisors Inc. ADV, Los Angeles Capital Management & Equity Research Inc., Country Trust Bank, Virtu Financial LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $268.13.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $12.09 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.
What is ABIOMED's official website?
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
